The significant earnings miss likely pressures MNKD near term, but upcoming PDUFA catalysts (Afrezza pediatric, Furoscix ReadyFlow) may limit downside. Traders should monitor for any pre-approval signals and upcoming Phase 2 data for nintedanib DPI.
MNKD drugs
MNKD drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 7 $3.55entry
- T+1 · 6mo ago 0.00%α −0.83% · $3.55
- T+5 · 6mo ago −9.58%α −11.08% · $3.21
- T+20 · 6mo ago −5.35%α −8.49% · $3.36
- T+60 · 4mo ago +7.04%α +3.21% · $3.80
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MannKind reported Q1 2026 GAAP EPS of -$0.05, a 600% miss vs. consensus of $0.01, and revenue of $90.2M, 14.4% below the $105.3M estimate. The miss was driven by a 116% surge in SG&A from Furoscix expansion and R&D ramp-up, despite a 15% YoY revenue increase. Pipeline catalysts (Afrezza pediatric PDUFA May 29, Furoscix ReadyFlow PDUFA July 26) provide optionality but do not offset the earnings disappointment.
Key Financial Metrics
Key Facts
- GAAP EPS -$0.05 vs. consensus $0.01 (-600% miss)
- Revenue $90.2M vs. consensus $105.3M (-14.4% miss)
- YoY revenue growth 15% ($78.4M to $90.2M)
- SG&A expenses increased 116% to $54.1M
- Net loss $16.6M vs. net income $13.2M in Q1 2025
- Cash and investments $134M at quarter end
- Key upcoming PDUFA dates: Afrezza pediatric May 29, Furoscix ReadyFlow July 26
Financial Impact
Q1 EPS miss of $0.06 per share and revenue miss of $15.1M
Risk Factors
- Failed regulatory approvals for Afrezza pediatric or Furoscix ReadyFlow
- Continued elevated operating expenses without commensurate revenue growth
- Potential further dilution from debt settlements
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3289304 |
Track record
17 reports on MNKD
6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +20.00% at T+60 after the May 27, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.23 Now $3.96 −6.38% settles Dec 9
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Bearish 5/10 Entry $3.90 Now $3.96 −1.54% settles Dec 7
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $3.73 Now $3.96 +6.17% settles Dec 2
- Jul 29, 202615w ago Press Release Bullish 6/10 Entry $3.85 to $4.09 Now $3.96 +2.86% ▲ +6.23% +1.21% vs SPY
- Jul 24, 202616w ago 8-K Mixed 6/10 Entry $3.95 to $4.07 Now $3.96 +0.25% ▲ +3.04% −0.26% vs SPY
- Jul 17, 202617w ago Insider Cluster Neutral 3/10 Entry $3.98 to $3.90 Now $3.96 −0.50% ▼ −2.01% −6.13% vs SPY
- Jun 3, 202623w ago Press Release Neutral 5/10 Entry $3.36 to $4.52 Now $3.96 +17.86% ▲ +34.52% +35.52% vs SPY
- Jun 2, 202623w ago 8-K Bullish 7/10 Entry $3.43 to $4.05 Now $3.96 +15.45% ▲ +18.08% +19.64% vs SPY
- May 29, 202624w ago Press Release Bullish 8/10 Entry $3.77 to $4.24 Now $3.96 +5.04% ▲ +12.47% +14.26% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers